Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00950807 · ClinicalTrials.gov registry record · Phase 2
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT00950807 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 176 participants.
The verdict
NCT00950807, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
Interventions
- DRUG Placebo
- DRUG Tiotropium
- DRUG GSK573179
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2009-09-01 |
| Est. Completion | 2010-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00950807
The ClinicalTrials.gov registry entry for NCT00950807 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00950807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00950807 about?
NCT00950807 is a clinical study titled "GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease". The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
What is the current status of trial NCT00950807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2009-09-01. Estimated completion is 2010-03-15.
What interventions are being tested in trial NCT00950807?
The interventions under investigation include: Placebo (DRUG), Tiotropium (DRUG), GSK573179 (DRUG).
Who is sponsoring clinical trial NCT00950807?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.